（1）国家自然科学基金面上项目, 2026-01-01 至 2029-12-31，50万元，在研，主持
（2）江苏省自然科学基金面上项目，2025-09-01 至 2028-12-31，15万元，在研，主持
（3）国家自然科学基金青年基金项目，82103978，2022-01-01 至 2024-12-31，30万元，已结题，主持
（4）江苏省自然科学基金青年基金项目，BK20210423，2021-07 至 2024-06，20万元，已结题，主持
（5）中国博士后基金面上项目，2019M662007，2019-11至2022-06，8万元，已结题，主持
（6）2020年度江苏省博士后日常资助，2020-09至2022-07，16万元，已结题，主持

1.Xiong, S.; Yang, J.; Yang, M.; Xiao, M.; Ha, S.; Tao, W.; Ma, L.; Ji, C.; Xiang, H.*, Luo, G.S.*. Discovery of a highly potent and selective tyrosine kinase 2 (TYK2) degrader with in vivo therapeutic efficacy in a murine psoriasis model. J. Med. Chem. 2025, 68(7):7560-7578.
2.Xiao, M.; Ha, S.; Zhu, J.C.; Tao, W.X.; Fu, Z.X.; Wei, H.L.; Hou, Q.; Luo, G.S.*; Xiang, H.*. Structure-Activity Relationship (SAR) Studies of novel monovalent AR/AR-V7 dual degraders with potent efficacy against advanced prostate cancer. J. Med. Chem. 2024, 67, 5567–5590.
3.Ma, L.Y.; Chen, W.; Yang, M.; Ha, S.; Xiong, S.S.; Zhu, J.C.; Xiang, H.*, Luo, G.S.*. Discovery and proof of concept of potent dual Polθ/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors. J. Med. Chem. 2024, 67, 3606–3625.
4.Yang, M; Xiang, H* Luo, G.S.*. Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial. J. Med. Chem. 2024, 67, 17997–18016.
5.Luo, G.S.; Lin, X.; Vega-Medina, A.; Xiao, M.X.; Li, G.L.; Wei, H.L.; Velázquez-Martínez, C.*; Xiang, H.* Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation. J. Med. Chem. 2021;64:17098-17114. (IF: 7.446)
6.Luo, G.S.; Li, Z.B.; Lin, X.; Li, X.Y.; Chen, Y., Xi, K.; Xiao, M.X.; Wei, H.L.; Zhu, L.Z.*; Xiang, H.* Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo. Acta Pharm. Sin. B. 2021;11:1300-1314. (IF: 11.413; Cover story)
7.Luo, G.S.1; Lin, X.1; Ren, S.L.; Wu, S.J.; Wang, X.; Ma, L.; Xiang, H.* Development of Novel Tetrahydroisoquinoline-Hydroxamate Conjugates as Potent Dual SERDs/HDAC Inhibitors for the Treatment of Breast Cancer. Eur. J. Med. Chem. 2021;226:113870. (IF: 6.514)
8.Luo, G.S.1; Lin, X.1; Li, Z.B.; Xiao, M.; Li, X.; Zhang, D.; Xiang, H*. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator. Eur. J. Med. Chem. 2021;209:112910. (IF: 6.514)